← All trials
NCT03984760
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2019
- Primary completion
- Jun 30, 2020
- Completion date
- Oct 20, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 240
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Panion & BF Biotech Inc.Lead sponsor
- Panion & BF Biotech Inc.Collaborator
- Wuhan UniversityOverall official - principal investigator
- Qingdao UniversityOverall official - principal investigator
- Henan Provincal People's HospitalOverall official - principal investigator
- Tonghua Central HospitalOverall official - principal investigator
- Meihekou Central HospitalOverall official - principal investigator
- Guangzhou Medical UniversityOverall official - principal investigator
- Guangdong Pharmaceutical UniversityOverall official - principal investigator
- People's Liberation Army of ChinaOverall official - principal investigator
- Daping HospitalOverall official - principal investigator
- Dalian Medical UniversityOverall official - principal investigator
- Jilin UniversityOverall official - principal investigator
- Jiangxi Provincial People's HospitalOverall official - principal investigator
- Changhai HospitalOverall official - principal investigator
- China Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.